Compare WIA & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | WIA | MOLN |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.8M | 157.8M |
| IPO Year | N/A | 2021 |
| Metric | WIA | MOLN |
|---|---|---|
| Price | $8.25 | $4.33 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.75 |
| AVG Volume (30 Days) | ★ 39.2K | 5.2K |
| Earning Date | 01-01-0001 | 10-30-2025 |
| Dividend Yield | ★ 12.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,000.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.56 | $3.36 |
| 52 Week High | $8.91 | $5.91 |
| Indicator | WIA | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 39.17 | 53.51 |
| Support Level | $8.24 | $4.13 |
| Resistance Level | $8.29 | $4.57 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 25.00 | 54.03 |
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.